Broussoflavonol B restricts growth of ER-negative breast cancer stem-like cells

Anticancer Research

Volumn 33, Issue 5, 2013, Pages 1873-1879

  Guo, Mingxi ^a   Wang, Molin ^a   Zhang, Xintian ^a   Deng, Hao ^a   Wang, Zhao Yi ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Broussoflavonol B; Cancer stem like cells; Estrogen receptor

Indexed keywords

BROUSSOFLAVONOL B; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA36; FLAVONOL DERIVATIVE; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BARK; BREAST CANCER; CANCER GROWTH; CANCER STEM CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG POTENCY; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; MORUS; PRIORITY JOURNAL; STEADY STATE;

BROUSSOFLAVONOL B; CANCER STEM-LIKE CELLS; ESTROGEN RECEPTOR;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; BROUSSONETIA; CELL DIFFERENTIATION; CELL PROLIFERATION; ESTROGEN RECEPTOR ALPHA; FEMALE; FLAVONOLS; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; MOLECULAR STRUCTURE; NEOPLASTIC STEM CELLS; TUMOR CELLS, CULTURED;

EID: 84878181955     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Dontu G, El-Ashry D and Wicha MS: Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab 15: 193-197, 2004. (Pubitemid 38833988)
2. Reya T and Clevers H: Wnt signalling in stem cells and cancer. Nature 434: 843-850, 2005. (Pubitemid 40558990)
3. Oliveira LR, Jeffrey SS and Ribeiro-Silva A: Stem cells in human breast cancer. Histol Histopathol 25: 371-385, 2010.
4. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, Brown M, Viens P, Xerri L, Bertucci F, Stassi G, Dontu G, Birnbaum D and Wicha MS: Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 69: 1302-1313, 2009.
5. Fillmore CM and Kuperwasser C: Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 10: R25, 2008.
6. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988, 2003. (Pubitemid 36418143)
7. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS and Dontu G: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1: 555-567, 2007. (Pubitemid 350056407)
8. Morimoto K, Kim SJ, Tanei T, Shimazu K, Tanji Y, Taguchi T, Tamaki Y, Terada N and Noguchi S: Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci 100: 1062-1068, 2009.
9. Dean M: Cancer stem cells: Redefining the paradigm of cancer treatment strategies. Mol Interv 6: 140-148, 2006.
10. Diehn M and Clarke MF: Cancer stem cells and radiotherapy: New insights into tumor radioresistance. J Natl Cancer Inst 98: 1755-1757, 2006. (Pubitemid 46017927)
11. O'Brien CS, Howell SJ, Farnie G and Clarke RB: Resistance to endocrine therapy: Are breast cancer stem cells the culprits? J Mammary Gland Biol Neoplasia 14: 45-54, 2009.
12. Hambardzumyan D, Squatrito M and Holland EC: Radiation resistance and stem-like cells in brain tumors. Cancer Cell 10: 454-456, 2006. (Pubitemid 44854752)
13. Shafee N, Smith CR, Wei S, Kim Y, Mills GB, Hortobagyi GN, Stanbridge EJ and Lee EY: Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res 68: 3243-3250, 2008.
14. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y and Deuel TF: Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. Biochem Biophys Res Commun 336: 1023-1027, 2005. (Pubitemid 41383424)
15. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y and Deuel TF: A variant of estrogen receptor-α, hER-α36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci USA 103: 9063-9068, 2006. (Pubitemid 43902533)
16. Zou Y, Ding L, Coleman M and Wang ZY: Estrogen receptor-alpha (ER-α) suppresses expression of its variant ER-α36. FEBS Lett 583: 1368-1374, 2009.
17. Lee LM, Cao J, Deng H, Chen P, Gatalica Z and Wang ZY: ER-α36, a novel variant of ER-α, is expressed in ER-positive and - negative human breast carcinomas. Anticancer Res 28: 479-483, 2008.
18. Shi L, Dong B, Li Z, Lu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Wang ZY, Xie Y: Expression of ER-α36, a novel variant of estrogen receptor α, and resistance to tamoxifen treatment in breast cancer. J Clin Oncol 27: 3423-3429, 2009.
19. Kang L, Guo Y, Zhang X, Meng J and Wang ZY: A positive cross-regulation of HER2 and ER-alpha36 controls ALDH1 positive breast cancer cells. J Steroid Biochem Mol Biol 127: 262-268, 2011.
20. Guo FJ, Feng L, Huang C, Ding HX, Zhang XT, Wang ZY and Li YM: Prenylflavone derivatives from broussonetia papyrifera, inhibit maligant growth of breast cancer cells in vitro and in vivo. Phytochem. Lett, In Press.
21. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL and Wahl GM: Cancer stem cells - perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 66: 9339-9344, 2006.
22. Kang L and Wang ZY: Breast cancer cell growth inhibition by phenethyl isothiocyanate is associated with down-regulation of oestrogen receptor-α36. J Cell Mol Med 14: 1485-1493, 2010.
23. Jordan CT, Guzman ML and Noble M: Cancer stem cells. N Engl J Med 355: 1253-1261, 2006. (Pubitemid 44427449)
24. Hill RP and Rerris R: De-stemming cancer stem cells. J Netl Cancer Inst 99: 1435-1440, 2007.
25. Lombardo Y, Scopelliti A, Cammareri P, Todaro M, Iovino F, Ricci-Vitiani L, Gulotta G, Dieli F, de Maria R and Stassi G: Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. Gastroenterology 140: 297-309, 2011.